Oncology Meeting Innovations
Translating Innovation Into Patient Care
OMI Website Banner General.png

News

Event Recap: Multiple Myeloma Expert Forum

MM 2017.png

We recently hosted the Annual Multiple Myeloma Expert Forum, a one-and-a-half-day meeting showcasing the emerging drugs and targets invading the field of multiple myeloma. The event took place in Dallas, TX on August 11th and 12th, 2017. Key opinion leaders traveled from all over the country to present and discuss novel therapies, new molecular targets, and the evolution of care in multiple myeloma.

The meeting started out with an exciting section on the preclinical data that will influence the field of multiple myeloma in the near future. From intratumor heterogeneity, to mathematical models and upcoming imaging modalities, the experts discussed and debated the future of personalized treatment and how it can be applied in multiple myeloma.

A lively conversation ensued on Saturday morning about the rapidly growing world of immunomodulation. We discussed the potential and benefits of targeting molecules like CTLA-4, the PD-1/PD-L1 axis, and CD38. The experts also covered new targets in clinical development including HDAC11 and BCL2 inhibition.

The excitement continued through the afternoon when the role of cereblon modulators and first and second generation proteasome inhibitors was dissected among the leaders in the field. The clinical data and technology on CAR-T therapy was compared, and the experts deliberated on how and when they expect CAR-Ts to transform the treatment of multiple myeloma.

In summary, it was a very successful meeting about how the emerging preclinical and clinical data will influence treatment and drive the field of multiple myeloma forward. The meeting fostered great debate and discussion about the upcoming changes to myeloma treatment, and for that we thank the key opinion leaders that joined us and gratefully participated.

Our next Multiple Myeloma Expert Forum will be held on August 24th - 25th, 2018 in Dallas, Texas. 

Josh HayesComment